SCIEX, a global leader in life science analytical technologies, and Evosep, a life science tools company specializing in liquid chromatography separation, expand collaboration for the Evosep One to be compatible with the ZenoTOF 7600+ system, the SCIEX 7500+ system and the SCIEX 7500 system.

The Evosep One offers an unparalleled combination of high throughput, sensitivity and reproducibility, enabling labs to process up to 500 samples per day with reduced system downtime. Tailored for robustness, this system minimizes sample carryover and maximizes data quality, making it an invaluable tool for advancing proteomics in pharma and biotechnology.

“This strengthened collaboration with SCIEX enables us to deliver further robust, scalable solutions for the pharma and biotech industries, directly addressing the need for high-throughput, high-sensitivity proteomics,” added Eric Grumbach, VP of Business Development - Pharma. “As we continue to grow, these collaborations are essential for our mission to make proteomics a powerful tool for the development of life-saving drugs.”

“Over the past 3 years, we are excited to see this collaboration grow to encompass more of the SCIEX portfolio. This latest achievement will allow scientist to harness the power of ZT Scan DIA data to precisely quantify proteins with up to 10-fold improvement in throughput for protein quantitation. Utilizing the Evosep One with SPD methods provides the speed and flexibility of analysis which perfectly matches with the performance of ZT Scan DIA. Together, SCIEX and Evosep can work together to help advance clinical proteomic research,” said Jose Castro-Perez, Vice President, Product Management.

The Evosep One empowers researchers and clinicians to accelerate breakthroughs in disease understanding and personalized treatment development. To learn more about the Evosep One, visit https://www.evosep.com/evosep-one/.

About SCIEX

SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust. ​Advances in human wellness depend on the power of precise science.​

For more information, visit sciex.com. ​

Connect with us on LinkedIn, Facebook, X (Twitter) and Instagram.​

SCIEX is proud to be part of Danaher. ​

Danaher’s science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2024 DH Tech. Dev. Pte. Ltd. MKT-33274-A.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241022988193/en/